Abstract
In recent years, increasing numbers of patients infected with HIV-1 non-B subtypes have been treated with modern antiretroviral regimens. Therefore, a better knowledge of HIV drug resistance in non-B strains is crucial. Thus, we compared the mutational pathways involved in drug resistance among the most common non-B subtypes in Italy (F, C, and CRF02-AG) and the B subtype. In total, 2234 pol sequences from 1231 virologically failing patients from Central Italy were analyzed. The prevalence of resistance mutations in protease and reverse transcriptase between non-B and B subtypes has been evaluated. Among patients treated with nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) and with thymidine analogues (TA) experience, TAMs1 M41L and L210W were less prevalent in CRF02-AG, while TAMs2 T215F and K219E were more prevalent in the F subtype. In NRTI-treated patients having experience with abacavir, didanosine, tenofovir, or stavudine the K65R mutation was mostly prevalent in the C subtype. In non-NRTI (NNRTI)-treated patients infected by the C subtype the prevalence of K103N was lower than in patients infected with other subtypes, while the prevalence of Y181C and Y188L was higher compared to subtype B. The prevalence of Y181C was higher also in subtype F as compared to subtype B. In patients treated with protease inhibitors, L89V was predominantly found in CRF02-AG, while the TPV resistance mutation T74P was predominantly found in the C subtype. Some differences in the genotypic drug resistance have been found among patients infected with B, C, F, and CRF02-AG subtypes in relationship to treatment. These results may be useful for the therapeutic management of individuals infected with HIV-1 non-B strains.
| Original language | English |
|---|---|
| Pages (from-to) | 1285-1293 |
| Number of pages | 9 |
| Journal | AIDS Research and Human Retroviruses |
| Volume | 28 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 1 2012 |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Virology
- Infectious Diseases
Cite this
Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02-AG) in Italy. / Santoro, Maria Mercedes; Alteri, Claudia; Ronga, Luigi; Flandre, Philippe; Fabeni, Lavinia; Mercurio, Fabio; D'Arrigo, Roberta; Gori, Caterina; Palamara, Guido; Bertoli, Ada; Forbici, Federica; Salpini, Romina; Boumis, Evangelo; Tozzi, Valerio; Visco-Comandini, Ubaldo; Zaccarelli, Mauro; Van Houtte, Margriet; Pattery, Theresa; Narciso, Pasquale; Antinori, Andrea; Ceccherini-Silberstein, Francesca; Perno, Carlo Federico.
In: AIDS Research and Human Retroviruses, Vol. 28, No. 10, 01.10.2012, p. 1285-1293.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02-AG) in Italy
AU - Santoro, Maria Mercedes
AU - Alteri, Claudia
AU - Ronga, Luigi
AU - Flandre, Philippe
AU - Fabeni, Lavinia
AU - Mercurio, Fabio
AU - D'Arrigo, Roberta
AU - Gori, Caterina
AU - Palamara, Guido
AU - Bertoli, Ada
AU - Forbici, Federica
AU - Salpini, Romina
AU - Boumis, Evangelo
AU - Tozzi, Valerio
AU - Visco-Comandini, Ubaldo
AU - Zaccarelli, Mauro
AU - Van Houtte, Margriet
AU - Pattery, Theresa
AU - Narciso, Pasquale
AU - Antinori, Andrea
AU - Ceccherini-Silberstein, Francesca
AU - Perno, Carlo Federico
PY - 2012/10/1
Y1 - 2012/10/1
N2 - In recent years, increasing numbers of patients infected with HIV-1 non-B subtypes have been treated with modern antiretroviral regimens. Therefore, a better knowledge of HIV drug resistance in non-B strains is crucial. Thus, we compared the mutational pathways involved in drug resistance among the most common non-B subtypes in Italy (F, C, and CRF02-AG) and the B subtype. In total, 2234 pol sequences from 1231 virologically failing patients from Central Italy were analyzed. The prevalence of resistance mutations in protease and reverse transcriptase between non-B and B subtypes has been evaluated. Among patients treated with nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) and with thymidine analogues (TA) experience, TAMs1 M41L and L210W were less prevalent in CRF02-AG, while TAMs2 T215F and K219E were more prevalent in the F subtype. In NRTI-treated patients having experience with abacavir, didanosine, tenofovir, or stavudine the K65R mutation was mostly prevalent in the C subtype. In non-NRTI (NNRTI)-treated patients infected by the C subtype the prevalence of K103N was lower than in patients infected with other subtypes, while the prevalence of Y181C and Y188L was higher compared to subtype B. The prevalence of Y181C was higher also in subtype F as compared to subtype B. In patients treated with protease inhibitors, L89V was predominantly found in CRF02-AG, while the TPV resistance mutation T74P was predominantly found in the C subtype. Some differences in the genotypic drug resistance have been found among patients infected with B, C, F, and CRF02-AG subtypes in relationship to treatment. These results may be useful for the therapeutic management of individuals infected with HIV-1 non-B strains.
AB - In recent years, increasing numbers of patients infected with HIV-1 non-B subtypes have been treated with modern antiretroviral regimens. Therefore, a better knowledge of HIV drug resistance in non-B strains is crucial. Thus, we compared the mutational pathways involved in drug resistance among the most common non-B subtypes in Italy (F, C, and CRF02-AG) and the B subtype. In total, 2234 pol sequences from 1231 virologically failing patients from Central Italy were analyzed. The prevalence of resistance mutations in protease and reverse transcriptase between non-B and B subtypes has been evaluated. Among patients treated with nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) and with thymidine analogues (TA) experience, TAMs1 M41L and L210W were less prevalent in CRF02-AG, while TAMs2 T215F and K219E were more prevalent in the F subtype. In NRTI-treated patients having experience with abacavir, didanosine, tenofovir, or stavudine the K65R mutation was mostly prevalent in the C subtype. In non-NRTI (NNRTI)-treated patients infected by the C subtype the prevalence of K103N was lower than in patients infected with other subtypes, while the prevalence of Y181C and Y188L was higher compared to subtype B. The prevalence of Y181C was higher also in subtype F as compared to subtype B. In patients treated with protease inhibitors, L89V was predominantly found in CRF02-AG, while the TPV resistance mutation T74P was predominantly found in the C subtype. Some differences in the genotypic drug resistance have been found among patients infected with B, C, F, and CRF02-AG subtypes in relationship to treatment. These results may be useful for the therapeutic management of individuals infected with HIV-1 non-B strains.
UR - http://www.scopus.com/inward/record.url?scp=84863546406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863546406&partnerID=8YFLogxK
U2 - 10.1089/aid.2011.0142
DO - 10.1089/aid.2011.0142
M3 - Article
C2 - 22417570
AN - SCOPUS:84863546406
VL - 28
SP - 1285
EP - 1293
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
SN - 0889-2229
IS - 10
ER -